{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:54:38Z","timestamp":1779256478032,"version":"3.51.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study investigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitalization of 614 hypertensive laboratory-confirmed COVID-19 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Demographics, comorbidities, vital signs, laboratory data, and ACEi\/ARB usage were analyzed. To account for confounders, patients were substratified by whether they developed hypotension and acute kidney injury (AKI) during the index hospitalization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mortality (22% vs 17%, P\u2005&amp;gt;\u2005.05) and intensive care unit (ICU) admission (26% vs 12%, P\u2005&amp;gt;\u2005.05) rates were not significantly different between non-ACEi\/ARB and ACEi\/ARB groups. However, patients who continued ACEi\/ARBs in the hospital had a markedly lower ICU admission rate (12% vs 26%; P\u2005=\u2005.001; odds ratio [OR]\u2005=\u20050.347; 95% confidence interval [CI], .187\u2013.643) and mortality rate (6% vs 28%; P\u2005=\u2005.001; OR\u2005=\u20050.215; 95% CI, .101\u2013.455) compared to patients who discontinued ACEi\/ARB. The odds ratio for mortality remained significantly lower after accounting for development of hypotension or AKI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings suggest that continued ACEi\/ARB use in hypertensive COVID-19 patients yields better clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa447","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T19:09:42Z","timestamp":1595012982000},"page":"1256-1264","source":"Crossref","is-referenced-by-count":102,"title":["Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome"],"prefix":"10.1093","volume":"222","author":[{"given":"Katherine W","family":"Lam","sequence":"first","affiliation":[{"name":"Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth W","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S","family":"Richman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep K","family":"Mallipattu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hal A","family":"Skopicki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6403-2827","authenticated-orcid":false,"given":"Tim Q","family":"Duong","sequence":"additional","affiliation":[{"name":"Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"2020091405343598800_CIT0001","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2020091405343598800_CIT0002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"2020091405343598800_CIT0003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"2020091405343598800_CIT0004","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2020091405343598800_CIT0005","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"2020091405343598800_CIT0006","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2020091405343598800_CIT0007","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbrc.2020.02.151","article-title":"Upregulation of angiotensin converting enzyme 2 by shear stress reduced inflammation and proliferation in vascular endothelial cells","volume":"525","author":"Song","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"2020091405343598800_CIT0008","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"2020091405343598800_CIT0009","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/eurheartj\/ehaa311","article-title":"Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts","volume":"41","author":"Nicin","year":"2020","journal-title":"Eur Heart J"},{"key":"2020091405343598800_CIT0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2020091405343598800_CIT0011","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2020091405343598800_CIT0012","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijid.2020.04.058","article-title":"Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity","volume":"95","author":"Ruocco","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2020091405343598800_CIT0013","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41440-020-0433-1","article-title":"Antihypertensive treatment with ACEI\/ARB of patients with COVID-19 complicated by hypertension","volume":"43","author":"Li","year":"2020","journal-title":"Hypertens Res"},{"key":"2020091405343598800_CIT0014","article-title":"COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease","author":"Tomasoni","journal-title":"Eur J Heart Fail"},{"key":"2020091405343598800_CIT0015","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"2020091405343598800_CIT0016","doi-asserted-by":"crossref","first-page":"e57278","DOI":"10.7554\/eLife.57278","article-title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","volume":"9","author":"Rossi","year":"2020","journal-title":"Elife"},{"key":"2020091405343598800_CIT0017","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","volume":"108","author":"Sriram","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2020091405343598800_CIT0018","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"2020091405343598800_CIT0019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"2020091405343598800_CIT0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2020091405343598800_CIT0021","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2020091405343598800_CIT0022","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"2020091405343598800_CIT0023","author":"American","year":"2020"},{"key":"2020091405343598800_CIT0024","author":"American College of Cardiology","year":"2020"},{"key":"2020091405343598800_CIT0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40292-020-00380-3","article-title":"Renin-angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A statement of activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension","volume":"27","author":"Iaccarino","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2020091405343598800_CIT0026","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.dsx.2020.03.016","article-title":"Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2020091405343598800_CIT0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2020.05.011","article-title":"Cohort of four thousand four hundred four persons under investigation for COVID-19 in a New York hospital and predictors of ICU care and ventilation","author":"Singer","year":"2020","journal-title":"Ann Emerg Med"},{"key":"2020091405343598800_CIT0028","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"2020091405343598800_CIT0029","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1753944716642677","article-title":"Cardiac remodelling and RAS inhibition","volume":"10","author":"Ferrario","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2020091405343598800_CIT0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"2020091405343598800_CIT0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2020091405343598800_CIT0032","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","article-title":"Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade","volume":"21","author":"Dandona","year":"2007","journal-title":"J Hum Hypertens"},{"key":"2020091405343598800_CIT0033","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/cvr\/cvaa086","article-title":"Inside the heart of COVID-19","volume":"116","author":"Ad\u00e3o","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2020091405343598800_CIT0034","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","article-title":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19","volume":"43","author":"Kai","year":"2020","journal-title":"Hypertens Res"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa447\/33651816\/jiaa447.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/8\/1256\/33744357\/jiaa447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/8\/1256\/33744357\/jiaa447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T09:35:28Z","timestamp":1600076128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/8\/1256\/5875659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,23]]},"published-print":{"date-parts":[[2020,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa447","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,15]]},"published":{"date-parts":[[2020,7,23]]}}}